Atle Fund Management AB
$372M 13F equity value
42 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Atle Fund Management AB covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29,821 | $36M | 9.6% |
| MRK | MERCK & CO. INC | 189,357 | $24M | 6.5% |
| JNJ | JOHNSON & JOHNSON | 85,425 | $22M | 5.8% |
| ABBV | ABBVIE INC | 64,325 | $16M | 4.4% |
| CVS | CVS HEALTH CORP | 146,102 | $15M | 4.1% |
| TMO | THERMO FISHER SCIENTIFIC CORP | 27,859 | $14M | 3.8% |
| RVMD | REVOLUTION MEDICINES INC | 73,077 | $14M | 3.7% |
| BIIB | BIOGEN INC | 62,781 | $14M | 3.6% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 72,898 | $12M | 3.3% |
| MIRM | MIRUM PHARMACEUTICALS INC | 100,807 | $12M | 3.2% |
Track Atle Fund Management AB's 13F portfolio: $372M in reported holdings, 42 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}